Response to "Tocilizumab therapy and COVID-19"

Affiliations

Free article

Comment

Pallavi Bhargava. J Osteopath Med. 2021.

Free article

. 2021 Sep 8;121(11):867-868.

doi: 10.1515/jom-2021-0212.

¹ Division of Infectious Disease, Department of Internal Medicine, Henry Ford Health System, 2799 West Grand Blvd, Detroit, MI 48202, USA.

No abstract available

Comment on

Tocilizumab therapy and COVID-19.
Mungmunpuntipantip R, Wiwanitkit V. Mungmunpuntipantip R, et al. J Osteopath Med. 2021 Aug 13;121(11):865. doi: 10.1515/jom-2021-0181. J Osteopath Med. 2021. PMID: 34388326 No abstract available.

1. Mungmunpuntipantip, R, Wiwanitkit, V. Tocilizumab therapy and COVID-19. J Osteopath Med 2021;121:865.https://doi.org/10.1515/jom-2021-0181.
1. Saffo, Z, Guo, W, Springer, K, Maksimowicz-McKinnon, K, Kak, V, McKinnon, JE, et al.. The role of tocilizumab therapy in critically ill patients with severe acute respiratory syndrome coronavirus 2. J Osteopath Med 2021;121:705–14. https://doi.org/10.1515/jom-2020-0292.
1. Investigators, REMAP-CAP, Gordon, AC, Mouncey, PR, Al-Beidh, F, Rowan, KM, Nichol, AD, et al.. Interleukin-6 receptor antagonists in critically ill patients with COVID-19. N Engl J Med 2021;384:1491–502. https://doi.org/10.1056/NEJMoa2100433.
1. RECOVERY Collaborative Group. Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. Lancet 2021;397:1637–45. https://doi.org/10.1016/S0140-6736(21)00676-0.
1. The WHO Rapid Evidence Appraisal for COVID-19 Therapies (REACT) Working Group. Association between administration of IL-6 antagonists and mortality among patients hospitalized for COVID-19: a meta-analysis. J Am Med Assoc. 2021;326:499–518. https://doi.org/10.1001/jama.2021.11330.